Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report-Reference-Cited by-同舟云学术

Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report

Published:2017-01-10 Issue:1 Volume:11 Page:
ISSN:1752-1947
Container-title:Journal of Medical Case Reports
language:en
Short-container-title:J Med Case Reports

Author:

Elm’hadi Choukri,Khmamouche Mohamed Reda,Tanz Rachid,Toreis Mehdi,Mahtat ElMehdi,Allaoui Mohammed,Oukabli Mohammed,Messaoudi Nezha,Errihani Hassan,Ichou Mohammed

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13256-016-1180-4.pdf

Reference16 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86. doi: 10.1002/ijc.29210 .

2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. CA Cancer J Clin. 2014;64:52–62. doi: 10.3322/caac.21203 .

3. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683–92. doi: 10.1038/nrclinonc.2010.154 .

4. Singhal M, Raina V, Gupta R, Das P. T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J. 2010;7(12):683–92. doi: 10.1186/1757-1626-3-4 .

5. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III: leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;37 suppl 2:S68–97.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report;Heliyon;2024-09

2. Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages;International Immunopharmacology;2020-01

3. Antineoplastics;Reactions Weekly;2017-04